Complete Genomics

Complete Genomics

Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $170M

Overview

Complete Genomics is a private company driving innovation in genomics through its proprietary DNBSEQ™ sequencing technology and Stereo-seq spatial transcriptomics platform. It offers a comprehensive suite of solutions, from benchtop to ultra-high-throughput sequencers, kits, reagents, and software, primarily for the research and clinical research markets. The company is strategically focused on establishing WGS as the new clinical gold standard and expanding its ecosystem through key partnerships with service providers and technology integrators.

Genetics & GenomicsDiagnostics

Technology Platform

DNBSEQ™ technology uses rolling circle replication to create DNA nanoballs (DNBs) for PCR-free, high-accuracy sequencing on a patterned array flow cell. Its Stereo-seq platform enables spatial transcriptomics with nanoscale resolution and a large capture area for tissue-wide analysis.

Funding History

3
Total raised:$170M
IPO$90M
Series B$50M
Series A$30M

Opportunities

The shift towards Whole Genome Sequencing as a clinical research gold standard and the rapid growth of the spatial biology market present significant growth opportunities.
Complete Genomics' DNBSEQ technology is positioned to enable the scalable $100 genome, while its Stereo-seq platform addresses the need for high-resolution, large-capture-area spatial analysis.

Risk Factors

Key risks include intense competition from established market leader Illumina, the challenge of driving technology adoption in a market with high switching costs, integration risks associated with the pending acquisition by Swiss Rockets AG, and fierce competition in the spatial omics segment.

Competitive Landscape

Complete Genomics primarily competes with Illumina in the NGS instrument market, differentiating on accuracy and cost-per-genome via its DNBSEQ technology. In spatial transcriptomics, it competes with 10x Genomics, Nanostring, and Vizgen, competing on the basis of Stereo-seq's superior resolution and large capture area.